These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 22440974)
1. DAI-10 is as good as DAI-30 in schizophrenia. Nielsen RE; Lindström E; Nielsen J; Levander S Eur Neuropsychopharmacol; 2012 Oct; 22(10):747-50. PubMed ID: 22440974 [TBL] [Abstract][Full Text] [Related]
2. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study. Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164 [TBL] [Abstract][Full Text] [Related]
5. [Relationships between insight and medication adherence in subjects with psychosis]. Droulout T; Liraud F; Verdoux H Encephale; 2003; 29(5):430-7. PubMed ID: 14615692 [TBL] [Abstract][Full Text] [Related]
6. A modified Drug Attitude Inventory used in long-term patients in sheltered housing. Stjernswärd S; Persson K; Nielsen R; Tuninger E; Levander S Eur Neuropsychopharmacol; 2013 Oct; 23(10):1296-9. PubMed ID: 23265955 [TBL] [Abstract][Full Text] [Related]
7. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906 [TBL] [Abstract][Full Text] [Related]
8. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Kim JH; Kim SY; Ahn YM; Kim YS Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807 [TBL] [Abstract][Full Text] [Related]
9. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241 [TBL] [Abstract][Full Text] [Related]
10. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle. Bech P; Tanghøj P; Andreasson K; Overø KF Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900 [TBL] [Abstract][Full Text] [Related]
11. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Gaebel W; Riesbeck M; von Wilmsdorff M; Burns T; Derks EM; Kahn RS; Rössler W; Fleischhacker WW; Eur Neuropsychopharmacol; 2010 May; 20(5):310-6. PubMed ID: 20202800 [TBL] [Abstract][Full Text] [Related]
12. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366 [TBL] [Abstract][Full Text] [Related]
13. [Drug compliance and health locus of control in schizophrenia]. Combes C; Feral F Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328 [TBL] [Abstract][Full Text] [Related]
14. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641 [TBL] [Abstract][Full Text] [Related]
15. Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient. Berecz R; Glaub T; Kellermann M; de la Rubia A; Llerena A; Degrell I Pharmacopsychiatry; 2000 Jan; 33(1):42-4. PubMed ID: 10721883 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotic medication in the treatment of schizophrenia. Kane JM Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642 [TBL] [Abstract][Full Text] [Related]
17. Cultural translation and Tunisian validation of the Drug Attitude Inventory (DAI-30) in outpatients with schizophrenia. Nakhli J; Amamou B; Mlika S; Bouhlel S; Trifi M; Nasr SB; El Kissi Y; Ali BB Compr Psychiatry; 2015 Jan; 56():69-74. PubMed ID: 25270281 [TBL] [Abstract][Full Text] [Related]
18. [Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish version]. Robles García R; Salazar Alvarado V; Páez Agraz F; Ramírez Barreto F Actas Esp Psiquiatr; 2004; 32(3):138-42. PubMed ID: 15168263 [TBL] [Abstract][Full Text] [Related]
19. Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. al-Semaan Y Can J Psychiatry; 1996 Sep; 41(7):484-5. PubMed ID: 8884041 [No Abstract] [Full Text] [Related]
20. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice]. Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]